SIRVENIB

NCT01135056 📎

Regimen

Experimental
SIRT with yttrium-90 resin microspheres
Control
sorafenib

Population

Locally advanced hepatocellular carcinoma without extrahepatic disease, not suitable for surgery/transplant/ablation (Asia-Pacific)

Key finding

Protocol paper for SIRveNIB — the companion Asia-Pacific trial to SARAH. Final readout (Chow 2018 JCO, PMID 29498924): mOS 8.8 vs 10.0 mo, HR 1.1, NS. Also negative for Y-90 superiority over sorafenib.

Source: PMID 27821083

Timeline

    Guideline citations

    • NCCN HCC (p.24)